XL413 is primarily used in research settings to study its effects on cell cycle regulation and DNA replication. It is a potent and selective inhibitor of CDC7 kinase, an enzyme crucial for the initiation of DNA replication. By inhibiting CDC7, XL413 can halt the proliferation of cancer cells, making it a valuable tool in oncology research for understanding tumor growth and developing potential anticancer therapies. Additionally, it is utilized in studies exploring the mechanisms of DNA damage response and cellular replication processes. Its application extends to preclinical investigations aimed at identifying novel therapeutic strategies for targeting cancers with high replication stress. Currently, XL413 is in clinical trials to evaluate its efficacy and safety in treating various types of cancer, with potential for combination therapies such as with radiation or chemotherapy.